2024
Absence of Anti-Babesia microti antibody in commercial intravenous immunoglobulin (IVIG)
Kostka J, Maharjan A, Kumar S, Hackenyos D, Krause P, Dieckhaus K. Absence of Anti-Babesia microti antibody in commercial intravenous immunoglobulin (IVIG). PLOS Neglected Tropical Diseases 2024, 18: e0012035. PMID: 38484010, PMCID: PMC10965045, DOI: 10.1371/journal.pntd.0012035.Peer-Reviewed Original ResearchConceptsIntravenous immunoglobulinB. microti antibodiesBabesiosis patientsSpectrum of disease severityCommercial intravenous immunoglobulinEffective treatment strategiesSevere organ damageHost antibody responseImmunocompromised patientsAdjunctive therapyOrgan damageTreatment strategiesAcute andClinical trialsMicroti antibodiesAsymptomatic infectionAntibody responseTherapeutic benefitTherapeutic effectPatientsDisease severityAntibodiesImmunofluorescence assayProtozoan infectionsCommercial samples
2019
Immunoepidemiology of Immune Dysfunction
Meffre E, Krause P, Ruddle N. Immunoepidemiology of Immune Dysfunction. 2019, 127-148. DOI: 10.1007/978-3-030-25553-4_8.ChaptersFood allergyAutoimmune diseasesIgE antibodiesRisk factorsPathogenic mechanismsImmediate hypersensitivity diseasesNon-IgE antibodiesIntravenous immunoglobulin therapySystemic lupus erythematosusBone marrow transplantationPrimary immune deficiencyT cell selectionAcquired etiologiesImmunoglobulin therapyHypersensitivity diseasesImmune dysfunctionLupus erythematosusFood intoleranceInfluence of lifestyleMarrow transplantationRheumatoid arthritisHLA typesImmune deficiencyLymphoproliferative syndromeTreatment strategies